IN2015DN03235A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN03235A IN2015DN03235A IN3235DEN2015A IN2015DN03235A IN 2015DN03235 A IN2015DN03235 A IN 2015DN03235A IN 3235DEN2015 A IN3235DEN2015 A IN 3235DEN2015A IN 2015DN03235 A IN2015DN03235 A IN 2015DN03235A
- Authority
- IN
- India
- Prior art keywords
- benzene
- membered nitrogen
- optionally fused
- containing heteroaryl
- therapy
- Prior art date
Links
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000004572 zinc-binding Effects 0.000 abstract 1
- 108010088577 zinc-binding protein Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220029.1A GB201220029D0 (en) | 2012-11-07 | 2012-11-07 | Compounds |
| GB201309015A GB201309015D0 (en) | 2013-05-20 | 2013-05-20 | Compounds |
| GB201315254A GB201315254D0 (en) | 2013-08-28 | 2013-08-28 | Compounds |
| PCT/GB2013/052917 WO2014072714A1 (en) | 2012-11-07 | 2013-11-06 | Novel histone deacetylase inhibitors and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03235A true IN2015DN03235A (enrdf_load_stackoverflow) | 2015-10-02 |
Family
ID=49585430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3235DEN2015 IN2015DN03235A (enrdf_load_stackoverflow) | 2012-11-07 | 2013-11-06 |
Country Status (11)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5597649B2 (ja) | 2009-01-28 | 2014-10-01 | カルス セラピューティクス リミテッド | スクリプタイドアイソスター（ｓｃｒｉｐｔａｉｄｉｓｏｓｔｅｒｅｓ）およびその治療における使用 |
| IN2015DN03235A (enrdf_load_stackoverflow) * | 2012-11-07 | 2015-10-02 | Karus Therapeutics Ltd | |
| PT2994465T (pt) | 2013-05-10 | 2018-10-25 | Karus Therapeutics Ltd | Novos inibidores de histona desacetilase |
| AU2015274334B2 (en) * | 2014-06-12 | 2020-12-17 | Cedars-Sinai Medical Center | Compositions and methods for treating cancers |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| ES2983284T3 (es) * | 2018-01-09 | 2024-10-22 | Shuttle Pharmaceuticals Inc | Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| US4792562A (en) * | 1985-12-04 | 1988-12-20 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyrrol-1-yl)pyridinamines having memory enhancing activity |
| JPH0532662A (ja) | 1990-11-09 | 1993-02-09 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| WO1997040017A2 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| EP0887348A1 (en) | 1997-06-25 | 1998-12-30 | Boehringer Mannheim Italia S.p.A. | Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them |
| JP3712529B2 (ja) | 1998-04-24 | 2005-11-02 | 大鵬薬品工業株式会社 | ３，３−ジピリジルアクリル酸アミド誘導体又はその薬学的に許容される塩 |
| AU769864B2 (en) | 1999-02-12 | 2004-02-05 | Hoya Corporation | Eyeglass and its manufacturing method |
| JP5278983B2 (ja) | 1999-11-17 | 2013-09-04 | 塩野義製薬株式会社 | アミド化合物の新規用途 |
| GB9929988D0 (en) | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
| JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| US6635640B2 (en) | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| WO2002034748A1 (en) * | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Imidazopyridine derivatives |
| JP2002255964A (ja) * | 2000-10-24 | 2002-09-11 | Sankyo Co Ltd | イミダゾピリジン誘導体 |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| EP1485099B1 (en) | 2002-03-13 | 2010-07-07 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
| JP2003313126A (ja) * | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
| JP2004002826A (ja) * | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| JP4235726B2 (ja) * | 2002-11-19 | 2009-03-11 | 国立大学法人 奈良先端科学技術大学院大学 | 大きな二光子吸収特性を示すアセチレン結合により連結されたビス（イミダゾリルポルフィリン金属錯体）を構成単位とするポルフィリン連鎖体及びその製造方法 |
| AU2003900608A0 (en) | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| AU2005217320B2 (en) | 2004-02-26 | 2011-07-21 | Aska Pharmaceuticals Co., Ltd. | Pyrimidine derivative |
| NZ551292A (en) * | 2004-06-01 | 2009-11-27 | Hoffmann La Roche | 3-Amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
| JP2008515821A (ja) | 2004-10-06 | 2008-05-15 | レセプトイコン・アンパルトセルスカブ | 薬物誘発性細胞毒性の予防のための化合物の使用 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| JP2008530136A (ja) | 2005-02-14 | 2008-08-07 | ミイカナ セラピューティクス インコーポレイテッド | ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物 |
| ES2380795T3 (es) | 2005-05-20 | 2012-05-18 | Vertex Pharmaceuticals, Inc. | Pirrolopiridinas útiles como inhibidores de proteínas quinasas |
| TW200716545A (en) * | 2005-06-10 | 2007-05-01 | Sigma Tau Ind Farmaceuti | Indole derivatives having anti-tumor activity |
| EP1940406A4 (en) | 2005-10-21 | 2009-11-18 | Merck & Co Inc | POTASSIUM CHANNEL INHIBITORS |
| US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| WO2007085540A1 (en) | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
| WO2007127183A1 (en) | 2006-04-26 | 2007-11-08 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| AU2007242594A1 (en) | 2006-04-26 | 2007-11-01 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as PI3K inhibitors |
| CA2658097A1 (en) | 2006-07-13 | 2008-01-17 | Kyowa Hakko Kirin Co., Ltd. | Pentadienamide derivatives |
| SG174790A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Tyrosine kinase inhibitors containing a zinc binding moiety |
| CA2667826C (en) | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP2089415A1 (en) | 2006-11-22 | 2009-08-19 | Karus Therapeutics Limited | Depsipeptides and their therapeutic use |
| MX2009008253A (es) | 2007-01-31 | 2009-10-12 | Vertex Pharma | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. |
| CN101663276A (zh) | 2007-01-31 | 2010-03-03 | 沃泰克斯药物股份有限公司 | 用作激酶抑制剂的2-氨基吡啶衍生物 |
| WO2008139987A1 (ja) | 2007-04-26 | 2008-11-20 | Japan Science And Technology Agency | Ｇタンパク質共役型レセプタ－作動剤 |
| WO2008137270A1 (en) * | 2007-05-04 | 2008-11-13 | H. Lundbeck A/S | Methods of diagnosing and monitoring of npy y5 based disorders |
| JP2010529031A (ja) | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体 |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| WO2009063240A1 (en) | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2010015520A1 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| US20110257170A1 (en) | 2008-10-03 | 2011-10-20 | Merck Serono Sa | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| JP5597649B2 (ja) * | 2009-01-28 | 2014-10-01 | カルス セラピューティクス リミテッド | スクリプタイドアイソスター（ｓｃｒｉｐｔａｉｄｉｓｏｓｔｅｒｅｓ）およびその治療における使用 |
| CN102498115B (zh) | 2009-08-20 | 2016-12-07 | 卡鲁斯治疗有限公司 | 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物 |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| DK2624832T3 (en) | 2010-10-08 | 2018-01-08 | Vib Vzw | HDAC INHIBITORS FOR TREATMENT OF CHARCOT-MARIE-TOOTHS DISEASE |
| KR20140099556A (ko) | 2010-12-16 | 2014-08-12 | 에프. 호프만-라 로슈 아게 | 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법 |
| USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| EP2508510A1 (en) | 2011-04-06 | 2012-10-10 | Ikerchem, S.L. | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof |
| AU2012319188B2 (en) | 2011-10-03 | 2016-11-24 | Sloan-Kettering Institute For Cancer Research | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| HK1200361A1 (en) * | 2011-10-04 | 2015-08-07 | 肝炎和病毒研究所 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
| CN103998042B (zh) | 2011-12-15 | 2016-12-28 | 诺华股份有限公司 | Pi3k的活性或功能的抑制剂的应用 |
| KR101415742B1 (ko) | 2011-12-21 | 2014-07-04 | 영남대학교 산학협력단 | 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| WO2014032019A2 (en) | 2012-08-23 | 2014-02-27 | Georgetown University | Compounds and methods of use thereof for treating tumors |
| IN2015DN03235A (enrdf_load_stackoverflow) * | 2012-11-07 | 2015-10-02 | Karus Therapeutics Ltd | |
| CN111904962A (zh) | 2012-11-08 | 2020-11-10 | 理森制药股份公司 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| US20160052926A1 (en) | 2013-03-15 | 2016-02-25 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
| WO2014153280A1 (en) | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| PT2994465T (pt) | 2013-05-10 | 2018-10-25 | Karus Therapeutics Ltd | Novos inibidores de histona desacetilase |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| WO2016031815A1 (ja) | 2014-08-26 | 2016-03-03 | 武田薬品工業株式会社 | 複素環化合物 |
| GB201419228D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
-
2013
- 2013-11-06 IN IN3235DEN2015 patent/IN2015DN03235A/en unknown
- 2013-11-06 MX MX2015005132A patent/MX364295B/es active IP Right Grant
- 2013-11-06 ES ES13792060.9T patent/ES2672701T3/es active Active
- 2013-11-06 US US14/441,401 patent/US9676765B2/en not_active Expired - Fee Related
- 2013-11-06 CA CA2888861A patent/CA2888861A1/en not_active Abandoned
- 2013-11-06 WO PCT/GB2013/052917 patent/WO2014072714A1/en active Application Filing
- 2013-11-06 JP JP2015540220A patent/JP6329958B2/ja not_active Expired - Fee Related
- 2013-11-06 CN CN201380058397.3A patent/CN104797573A/zh active Pending
- 2013-11-06 NZ NZ707366A patent/NZ707366A/en not_active IP Right Cessation
- 2013-11-06 EP EP13792060.9A patent/EP2917202B1/en not_active Not-in-force
- 2013-11-06 AU AU2013343291A patent/AU2013343291B2/en not_active Ceased
-
2017
- 2017-05-08 US US15/589,491 patent/US10150763B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9676765B2 (en) | 2017-06-13 |
| NZ707366A (en) | 2018-11-30 |
| AU2013343291B2 (en) | 2018-05-10 |
| WO2014072714A1 (en) | 2014-05-15 |
| EP2917202B1 (en) | 2018-05-02 |
| CN104797573A (zh) | 2015-07-22 |
| MX2015005132A (es) | 2015-12-07 |
| JP2015535273A (ja) | 2015-12-10 |
| ES2672701T3 (es) | 2018-06-15 |
| US20150361074A1 (en) | 2015-12-17 |
| US20180086750A1 (en) | 2018-03-29 |
| EP2917202A1 (en) | 2015-09-16 |
| US10150763B2 (en) | 2018-12-11 |
| AU2013343291A1 (en) | 2015-05-07 |
| JP6329958B2 (ja) | 2018-05-23 |
| MX364295B (es) | 2019-04-22 |
| CA2888861A1 (en) | 2014-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2875877C (en) | Syk inhibitors | |
| IN2015DN03235A (enrdf_load_stackoverflow) | ||
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| RS54873B1 (sr) | Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
| UA111382C2 (uk) | Інгібітори протеїнкінази | |
| EA201291282A1 (ru) | Азотсодержащие гетероарильные соединения | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| EA030199B9 (ru) | Терапевтически активные соединения и способы их применения | |
| EA201300200A1 (ru) | N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| TN2011000400A1 (en) | Inhibitors of beta-secretase | |
| EA024194B8 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| IN2014DN07509A (enrdf_load_stackoverflow) | ||
| MY172422A (en) | Pyrazole compound and pharmaceutical use thereof | |
| PH12012501643A1 (en) | Pyrazolopyrimidine compounds and their use as pde 10 inhibitors | |
| MX2017005422A (es) | Inhibidores de histona desacetilasa y sus usos en terapia. | |
| MX2015017156A (es) | Inhibidores de bace. | |
| NZ701933A (en) | Phenoxyethyl piperidine compounds | |
| MX364400B (es) | Compuestos de tetraciclina. | |
| MX2017005423A (es) | Inhibidores de histona desacetilasa y sus usos en terapia. | |
| PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| WO2012058127A3 (en) | Novel compounds that are erk inhibitors | |
| PH12015501056A1 (en) | 2-pyridone compound | |
| EA201301136A2 (ru) | Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
| EA201301235A1 (ru) | Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей |